The Bantam Pharmaceutical team is led and guided by a strong experienced team and advisory board with a proven track record of success in oncology drug discovery and development.
$25M
FUNDING RAISED
Founded Q4 2015 - Novel pathway and targets, and patented technology
Chair of SAB Managing Partner MPM Capitol CEO Syndax, Inc.
Mike Patane, PhD
Former CEO, Mitobridge (Astellas)
Mark Manfredi, PhD
CEO, Ikena Therapeutics EIR Atlas Venture
Joshua Rabinowitz, MD, PhD
Professor, Princeton University
Adrian Schwarzer, MD, PhD
Hematology/Oncology Hannover Medical School
MICHAEL LUTHER, PHD, MBA
Former Merck and GSK
Board of Managers
Michael Stocum
President, CEO Bantam Pharmaceutical
Victor Keen
OF COUNSEL AT DUANE MORRIS, LLP CO-CHAIR CARETEC GROUP, INC (OTC) FORMER BOARD MEMBER RESEARCH FRONTIERS, INC (NASD)
Lionel Goldfrank III
PRINCIPAL IN SEVERAL PRIVATE INVESTMENT COMPANIES FOUNDER OF AMERICAN & OVERSEAS ASSET SERVICES CORPORATION FORMERLY WITH GOLDMAN SACHS
W. James Tozer, Jr.
Co-owner and Founder Vectra Management Group Former Senior Executive Citicorp and President of Prudential Securities Founding Investor in LendingTree, Vectra Bank Colorado, and Draper Bank Bio-Tech Venture Investor in GangaGen, Iveena, PenBlade and PhotoPharmics
We are an early mover in the field of mitochondrial homeostasis, using our pioneering science and unrivaled expertise in mitochondrial cellular biology to revolutionize oncology
We are seeking partners and additional investors to accelerate our clinical research and help bring novel cancer therapies closer to patients in need
Bantam is seeking partners and investors to drive rapid clinical development of our first-in-class molecule from First in Humans trials to clinical Proof of Concept.
